Shacham Abulafia, A.; Shemesh, S.; Rosenmann, L.; Berger, T.; Leader, A.; Sharf, G.; Raanani, P.; Rozovski, U.
Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors. J. Clin. Med. 2020, 9, 3417.
https://doi.org/10.3390/jcm9113417
AMA Style
Shacham Abulafia A, Shemesh S, Rosenmann L, Berger T, Leader A, Sharf G, Raanani P, Rozovski U.
Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors. Journal of Clinical Medicine. 2020; 9(11):3417.
https://doi.org/10.3390/jcm9113417
Chicago/Turabian Style
Shacham Abulafia, Adi, Sivan Shemesh, Lena Rosenmann, Tamar Berger, Avi Leader, Giora Sharf, Pia Raanani, and Uri Rozovski.
2020. "Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors" Journal of Clinical Medicine 9, no. 11: 3417.
https://doi.org/10.3390/jcm9113417
APA Style
Shacham Abulafia, A., Shemesh, S., Rosenmann, L., Berger, T., Leader, A., Sharf, G., Raanani, P., & Rozovski, U.
(2020). Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors. Journal of Clinical Medicine, 9(11), 3417.
https://doi.org/10.3390/jcm9113417
